Edwards Lifesciences (NYSE:EW) Sets New 52-Week High on Analyst Upgrade

Edwards Lifesciences Corporation (NYSE:EW) shares hit a new 52-week high on Friday after Royal Bank Of Canada raised their price target on the stock from $95.00 to $100.00. Royal Bank Of Canada currently has an outperform rating on the stock. Edwards Lifesciences traded as high as $87.61 and last traded at $87.4180, with a volume of 767415 shares changing hands. The stock had previously closed at $85.78.

Other equities research analysts also recently issued research reports about the company. Barclays reissued an “overweight” rating and issued a $99.00 target price (up previously from $95.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $83.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. Canaccord Genuity Group set a $89.00 target price on shares of Edwards Lifesciences in a research report on Friday. Finally, Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $92.91.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at $25,000. Quantbot Technologies LP purchased a new position in Edwards Lifesciences during the first quarter worth about $26,000. SouthState Corp acquired a new stake in Edwards Lifesciences in the 1st quarter worth about $27,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at about $28,000. Finally, True Wealth Design LLC increased its stake in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

The company’s fifty day moving average price is $80.75 and its two-hundred day moving average price is $78.68. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm has a market capitalization of $50.92 billion, a PE ratio of 37.85, a price-to-earnings-growth ratio of 3.72 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.